<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="manner" type="rst"/>
			<rel name="result" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">6. Challenges in MSC Translation into Clinical Practice :</segment>
<segment id="2" parent="1002" relname="preparation">The Bone Disease Framework</segment>
<segment id="3" parent="1003" relname="span">Other interesting aspects and new perspectives in the field of tissue regeneration and applicative use of MSC are strictly related to their potential</segment>
<segment id="4" parent="1004" relname="span">to tackle the increase in bone diseases</segment>
<segment id="5" parent="4" relname="elaboration">related with the extended life expectancy .</segment>
<segment id="6" parent="1008" relname="span">Indeed , in many countries bone diseases are becoming a relevant cause of disability ,</segment>
<segment id="7" parent="6" relname="concession">even if they are acute , such as fractures , or chronic , such as osteoporosis and tumours .</segment>
<segment id="8" parent="1009" relname="span">In any case these pathologies require treatments</segment>
<segment id="9" parent="8" relname="purpose">to enhance the healing and regenerative capacity of bone tissue .</segment>
<segment id="10" parent="1011" relname="span">The common therapeutic strategies</segment>
<segment id="11" parent="1012" relname="span">based on bone grafting</segment>
<segment id="12" parent="11" relname="elaboration">( autografts or allografts )</segment>
<segment id="13" parent="1010" relname="same_unit">show some disadvantages .</segment>
<segment id="14" parent="1016" relname="span">Autografts are limited by the bone volume</segment>
<segment id="15" parent="14" relname="elaboration">that can be harvested from the iliac crest</segment>
<segment id="16" parent="1016" relname="elaboration">and present surgical risks such as bleeding , inflammation , infection , chronic pain , damage at the donor site and morbidity .</segment>
<segment id="17" parent="1018" relname="span">Allografts also have some limitations , such as the lack of donors , high costs , the need for sterilization and the risk of infectious agent transmission or immune mediated tissue rejection .</segment>
<segment id="18" parent="1019" relname="span">These limitations and disadvantages</segment>
<segment id="19" parent="1020" relname="span">associated with auto- and allograft approaches indicate a clinical need for alternative therapeutic strategies</segment>
<segment id="20" parent="19" relname="elaboration">aimed at bone healing and regeneration .</segment>
<segment id="21" parent="1021" relname="span">Thus , new biomaterials and scaffolds , in association with MSC and growth factors ,</segment>
<segment id="22" parent="1022" relname="span">having requirements of biocompatibility , osteoinductive and osteoconductive properties , are investigated</segment>
<segment id="23" parent="22" relname="purpose">to improve bone repair .</segment>
<segment id="24" parent="1024" relname="span">The use of MSC is attractive</segment>
<segment id="25" parent="1026" relname="concession">since they can be harvested from the host with minimal morbidity ,</segment>
<segment id="26" parent="1026" relname="joint">they can be modified to secrete osteoinductive factors</segment>
<segment id="27" parent="1027" relname="span">and implanted on an osteoconductive scaffold ,</segment>
<segment id="28" parent="1028" relname="span">to obtain the three key components</segment>
<segment id="29" parent="28" relname="elaboration">leading to osteogenesis .</segment>
<segment id="30" parent="1030" relname="span">hMSC have been found in several adult tissues ,</segment>
<segment id="31" parent="1031" relname="span">including the synovial membrane , the adipose tissue , the dental pulp tissue , or in perinatal tissues</segment>
<segment id="32" parent="31" relname="elaboration">( umbilical cord blood and umbilical cord tissue ) .</segment>
<segment id="33" parent="1035" relname="span">All these cells are suited to therapeutic applications for bone regeneration , by means of two different ways of autologous cells transplantation :</segment>
<segment id="34" parent="33" relname="elaboration">( 1 ) cell therapies without expansion in culture</segment>
<segment id="35" parent="1035" relname="elaboration">( one-step procedure )</segment>
<segment id="36" parent="1002" relname="joint">and ( 2 ) cell therapies with ex vivo expansion .</segment>
<segment id="37" parent="1002" relname="joint">In the first case , cells are harvested during surgery .</segment>
<segment id="38" parent="1038" relname="span">In 2010 , Jagër et al. , successfully treated more than 100 patients with local bone healing disorders</segment>
<segment id="39" parent="38" relname="means">using a biomaterial composite in association with BM aspiration concentrate .</segment>
<segment id="40" parent="41" relname="attribution">They observed</segment>
<segment id="41" parent="1041" relname="span">that the use of BM concentrate reduced the harvest of autogenous bone by 50 %</segment>
<segment id="42" parent="1041" relname="elaboration">without negative effects on bone healing .</segment>
<segment id="43" parent="1002" relname="joint">The second clinical application of MSC includes the autologous cell transplantation after ex-vivo expansion .</segment>
<segment id="44" parent="1044" relname="span">In 2007 , Nöth et al. , used a cell population from BM aspirate</segment>
<segment id="45" parent="1045" relname="joint">cultured over 12 days under GMP conditions</segment>
<segment id="46" parent="1045" relname="joint">and transplanted them autologously with a tricalcium phosphate biomaterial for the treatment of femoral head necrosis .</segment>
<segment id="47" parent="1002" relname="joint">The main limitations for clinical application are the sterility technique , long culture time , high cost , and the mixture of human cell culture medium with fetal bovine serum .</segment>
<segment id="48" parent="1050" relname="span">Thus , recently , orthopedic researchers focused their attention on the clinical use of BM aspirate</segment>
<segment id="49" parent="48" relname="restatement">( BMA )</segment>
<segment id="50" parent="1052" relname="span">and BM concentrate</segment>
<segment id="51" parent="50" relname="restatement">( BMC )</segment>
<segment id="52" parent="1051" relname="same_unit">for musculoskeletal regeneration with a “ one-step ” procedure ,</segment>
<segment id="53" parent="1053" relname="span">avoiding the need of additional laboratory stages and GMP facility ,</segment>
<segment id="54" parent="53" relname="result">thus reducing costs and risks .</segment>
<segment id="55" parent="1055" relname="span">Bone marrow contains MSC , hematopoietic stem cells , endothelial progenitor cells , other progenitor cells and growth factors ,</segment>
<segment id="56" parent="1057" relname="span">including bone morphogenetic proteins</segment>
<segment id="57" parent="56" relname="elaboration">( BMP ) ,</segment>
<segment id="58" parent="1059" relname="span">platelet-derived growth factor</segment>
<segment id="59" parent="58" relname="restatement">( PDGF ) ,</segment>
<segment id="60" parent="1061" relname="span">transforming growth factor-β</segment>
<segment id="61" parent="60" relname="elaboration">( TGF-β ) ,</segment>
<segment id="62" parent="1063" relname="span">vascular endothelial growth factor</segment>
<segment id="63" parent="62" relname="elaboration">( VEGF ) ,</segment>
<segment id="64" parent="1065" relname="span">interleukin-8</segment>
<segment id="65" parent="64" relname="elaboration">( IL-8 ) ,</segment>
<segment id="66" parent="1064" relname="same_unit">and IL-1 receptor antagonist .</segment>
<segment id="67" parent="1068" relname="joint">It has been identified as an excellent source of cells and growth factors</segment>
<segment id="68" parent="1068" relname="joint">and it has been used with success for bone , cartilage and soft tissue healing .</segment>
<segment id="69" parent="1069" relname="span">We focused our attention on the use of BM-derived MSC in spinal fusion surgical procedures ,</segment>
<segment id="70" parent="1071" relname="span">which is the most definitive treatment</segment>
<segment id="71" parent="70" relname="elaboration">performed</segment>
<segment id="72" parent="1071" relname="purpose">to restore the structural stability of the spinal column in degenerative and oncological spine diseases .</segment>
<segment id="73" parent="1073" relname="span">Currently , the gold standard stimulus</segment>
<segment id="74" parent="1074" relname="span">to achieve spinal fusion is autologous bone</segment>
<segment id="75" parent="74" relname="restatement">( autograft ) ,</segment>
<segment id="76" parent="1076" relname="contrast">which is commonly harvested from the iliac crest</segment>
<segment id="77" parent="1077" relname="span">or obtained from the surgical site</segment>
<segment id="78" parent="77" relname="elaboration">( local bone ) .</segment>
<segment id="79" parent="1080" relname="span">As autologous bone possesses osteogenic , osteoinductive and osteoconductive abilities ;</segment>
<segment id="80" parent="1081" relname="span">the success rate of spinal fusion with autograft is high</segment>
<segment id="81" parent="80" relname="restatement">( up to 95 % ) .</segment>
<segment id="82" parent="1082" relname="joint">However , autograft material is limited in quantity</segment>
<segment id="83" parent="1083" relname="span">and its quality varies</segment>
<segment id="84" parent="83" relname="elaboration">depending on the patient .</segment>
<segment id="85" parent="1085" relname="span">Moreover , significant morbidity is associated with bone harvesting ,</segment>
<segment id="86" parent="85" relname="manner">as previously described .</segment>
<segment id="87" parent="1088" relname="span">Between many alternatives</segment>
<segment id="88" parent="1089" relname="span">proposed</segment>
<segment id="89" parent="88" relname="purpose">to achieve spinal fusion ,</segment>
<segment id="90" parent="1090" relname="span">MSC are interesting</segment>
<segment id="91" parent="1091" relname="span">because they can provide osteogenic properties</segment>
<segment id="92" parent="91" relname="elaboration">allowing bone regeneration .</segment>
<segment id="93" parent="1093" relname="span">We recently published a descriptive systematic literature review</segment>
<segment id="94" parent="1095" relname="attribution">in order to understand</segment>
<segment id="95" parent="1095" relname="span">if the use of MSC may represent a valid strategy</segment>
<segment id="96" parent="95" relname="purpose">to facilitate and accelerate bone regeneration and fusion during spine surgery .</segment>
<segment id="97" parent="1097" relname="span">In this review we selected and analyzed 50 relevant papers ,</segment>
<segment id="98" parent="97" relname="elaboration">stratified according to preclinical studies and clinical trials .</segment>
<segment id="99" parent="1100" relname="attribution">Preclinical published data showed</segment>
<segment id="100" parent="1100" relname="span">that MSC have the potential</segment>
<segment id="101" parent="100" relname="purpose">to achieve , facilitate and accelerate spinal fusion .</segment>
<segment id="102" parent="103" relname="attribution">However , preclinical studies on animal models indicated</segment>
<segment id="103" parent="1102" relname="span">that some barriers remain prior to this therapy translation into the clinical application .</segment>
<segment id="104" parent="1103" relname="joint">So far , few published clinical studies employ stem cells for spinal fusion .</segment>
<segment id="105" parent="1104" relname="joint">Most of them used concentrated autologous BM as primary source of stem cells</segment>
<segment id="106" parent="1105" relname="span">and they showed fusion results</segment>
<segment id="107" parent="106" relname="elaboration">ranging from 87 % to 92.3 % in a total of 297 patients .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="multinuc" parent="1001" relname="span"/>
<group id="1003" type="span" parent="1002" relname="joint"/>
<group id="1004" type="span" parent="3" relname="purpose"/>
<group id="1006" type="span" parent="1002" relname="joint"/>
<group id="1007" type="span" parent="1006" relname="span"/>
<group id="1008" type="span" parent="1007" relname="span"/>
<group id="1009" type="span" parent="1008" relname="elaboration"/>
<group id="1010" type="multinuc" parent="1007" relname="elaboration"/>
<group id="1011" type="span" parent="1010" relname="same_unit"/>
<group id="1012" type="span" parent="10" relname="elaboration"/>
<group id="1015" type="span" parent="1002" relname="joint"/>
<group id="1016" type="span" parent="1015" relname="span"/>
<group id="1017" type="span" parent="1002" relname="joint"/>
<group id="1018" type="span" parent="1017" relname="span"/>
<group id="1019" type="span" parent="17" relname="elaboration"/>
<group id="1020" type="span" parent="18" relname="elaboration"/>
<group id="1021" type="span" parent="1018" relname="elaboration"/>
<group id="1022" type="span" parent="21" relname="elaboration"/>
<group id="1024" type="span" parent="1002" relname="joint"/>
<group id="1025" type="span" parent="24" relname="elaboration"/>
<group id="1026" type="multinuc" parent="1025" relname="span"/>
<group id="1027" type="span" parent="1026" relname="joint"/>
<group id="1028" type="span" parent="27" relname="purpose"/>
<group id="1030" type="span" parent="1002" relname="joint"/>
<group id="1031" type="span" parent="30" relname="elaboration"/>
<group id="1034" type="span" parent="1002" relname="joint"/>
<group id="1035" type="span" parent="1034" relname="span"/>
<group id="1038" type="span" parent="1002" relname="joint"/>
<group id="1040" type="span" parent="1002" relname="joint"/>
<group id="1041" type="span" parent="1040" relname="span"/>
<group id="1044" type="span" parent="1002" relname="joint"/>
<group id="1045" type="multinuc" parent="44" relname="elaboration"/>
<group id="1048" type="multinuc" parent="1002" relname="joint"/>
<group id="1049" type="multinuc" parent="1048" relname="same_unit"/>
<group id="1050" type="span" parent="1049" relname="same_unit"/>
<group id="1051" type="multinuc" parent="1049" relname="same_unit"/>
<group id="1052" type="span" parent="1051" relname="same_unit"/>
<group id="1053" type="span" parent="1048" relname="same_unit"/>
<group id="1055" type="span" parent="1002" relname="joint"/>
<group id="1056" type="multinuc" parent="55" relname="elaboration"/>
<group id="1057" type="span" parent="1056" relname="same_unit"/>
<group id="1058" type="span" parent="1056" relname="same_unit"/>
<group id="1059" type="span" parent="1058" relname="span"/>
<group id="1060" type="multinuc" parent="1059" relname="elaboration"/>
<group id="1061" type="span" parent="1060" relname="same_unit"/>
<group id="1062" type="multinuc" parent="1060" relname="same_unit"/>
<group id="1063" type="span" parent="1062" relname="same_unit"/>
<group id="1064" type="multinuc" parent="1062" relname="same_unit"/>
<group id="1065" type="span" parent="1064" relname="same_unit"/>
<group id="1067" type="span" parent="1002" relname="joint"/>
<group id="1068" type="multinuc" parent="1067" relname="span"/>
<group id="1069" type="span" parent="1068" relname="elaboration"/>
<group id="1070" type="span" parent="69" relname="elaboration"/>
<group id="1071" type="span" parent="1070" relname="span"/>
<group id="1072" type="span" parent="1002" relname="joint"/>
<group id="1073" type="span" parent="1072" relname="span"/>
<group id="1074" type="span" parent="73" relname="purpose"/>
<group id="1075" type="multinuc" parent="1073" relname="elaboration"/>
<group id="1076" type="multinuc" parent="1075" relname="joint"/>
<group id="1077" type="span" parent="1076" relname="contrast"/>
<group id="1078" type="multinuc" parent="1075" relname="joint"/>
<group id="1079" type="span" parent="1078" relname="joint"/>
<group id="1080" type="span" parent="1082" relname="concession"/>
<group id="1081" type="span" parent="79" relname="elaboration"/>
<group id="1082" type="multinuc" parent="1079" relname="span"/>
<group id="1083" type="span" parent="1082" relname="joint"/>
<group id="1084" type="multinuc" parent="1078" relname="joint"/>
<group id="1085" type="span" parent="1084" relname="joint"/>
<group id="1086" type="multinuc" parent="1084" relname="joint"/>
<group id="1087" type="multinuc" parent="1086" relname="joint"/>
<group id="1088" type="span" parent="1087" relname="same_unit"/>
<group id="1089" type="span" parent="87" relname="elaboration"/>
<group id="1090" type="span" parent="1087" relname="same_unit"/>
<group id="1091" type="span" parent="90" relname="cause"/>
<group id="1092" type="multinuc" parent="1086" relname="joint"/>
<group id="1093" type="span" parent="1092" relname="joint"/>
<group id="1094" type="span" parent="93" relname="purpose"/>
<group id="1095" type="span" parent="1094" relname="span"/>
<group id="1096" type="span" parent="1092" relname="joint"/>
<group id="1097" type="span" parent="1096" relname="span"/>
<group id="1098" type="multinuc" parent="1097" relname="elaboration"/>
<group id="1099" type="span" parent="1098" relname="contrast"/>
<group id="1100" type="span" parent="1099" relname="span"/>
<group id="1101" type="multinuc" parent="1098" relname="contrast"/>
<group id="1102" type="span" parent="1101" relname="joint"/>
<group id="1103" type="multinuc" parent="1101" relname="joint"/>
<group id="1104" type="multinuc" parent="1103" relname="joint"/>
<group id="1105" type="span" parent="1104" relname="joint"/>
	</body>
</rst>
